

## Technology Advisory Committee D Interests Register

**Topic: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]**

**Publication Date: TBC**

| Name               | Role with NICE       | Type of interest   | Description of interest   | Interest declared | Comments   |
|--------------------|----------------------|--------------------|---|-------------------|--|
| Dr Will Sullivan   | TAC Committee Member | Direct- financial  | In his role as a consultant, Will's employer is paid for him to provide consultancy services to various pharmaceutical companies. In the last 12 months, none of these companies are potential comparator companies for this topic. | 28/08/2024        | It was agreed that Dr Sullivan's declaration would not prevent them from participating in discussions on this appraisal. |
| Dr Matthew Bradley | TAC Committee Member | Direct- financial  | Dr Bradley holds shares in AstraZeneca, who are the submitting company for this appraisal   | 30/08/2024        | It was agreed that Dr Bradley's declaration would prevent them from participating in discussions on this appraisal.      |
| Shobhit Baijal     | Clinical Expert      | Direct – financial | Shobhit has done paid consultancy work for AstraZeneca  | 03/10/2024        | It was agreed that Shobhit's declaration would not prevent them from providing expert advice to the committee.           |